HEPAREGENIX GMBH has a total of 28 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are SYMPHONY EVOLUTION INC, VERSEON CORP and SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | Australia | 3 | |
#3 | Brazil | 3 | |
#4 | Canada | 3 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | China | 2 | |
#7 | Israel | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Singapore | 2 | |
#10 | United States | 2 | |
#11 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Laufer Stefan | 24 |
#2 | Selig Roland | 24 |
#3 | Albrecht Wolfgang | 24 |
#4 | Praefke Bent | 10 |
#5 | Klövekorn Phillip | 7 |
#6 | Präfke Bent | 7 |
#7 | Klövekorn Philip | 5 |
#8 | Stefan Laufer | 4 |
#9 | Prafke Bent | 4 |
#10 | Klovekorn Phillip | 4 |
Publication | Filing date | Title |
---|---|---|
WO2021018820A1 | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
KR20210035092A | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
EP3810139A1 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
EP3746437A1 | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
AU2018209164A1 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |